WHAT WE DO
WHAT WE DO… AND WHY
Often thought of as a disease of the past, tuberculosis continues to plague the world’s most vulnerable populations, with around 8.7 million new cases of TB globally each year and about 1.4 million deaths.
In some areas of the world, one in four people with TB has a drug-resistant form of the disease. Nearly 60% of worldwide MDR-TB cases occur in China, India, Russia and South Africa, with only 1 in 5 patients estimated to exist being diagnosed worldwide.
These statistics are even more dire considering that TB and MDR-TB are treatable and curable. The real problem lies in the fact that TB — in all its forms — is a complex disease, one that is not just a medical problem, but a social and economic problem as well.
Lilly MDR-TB PARTNERSHIP ON THE GROUND
Today, the Lilly MDR-TB Partnership is hard at work primarily in four target countries: China, India, Russia and South Africa, focusing our geographic reach and ‘Research, Report and Advocate’ approach to have an even deeper impact where the disease is most active.
- We have transferred manufacturing technology to seven companies to increase availability of MDR-TB medicines and improve standards of care
- The Partnership has trained over 100,000 healthcare professionals and nurses to better recognize, diagnose and treat MDR-TB and to provide care and support to people with MDR-TB and their families
- Guidelines and toolkits have been distributed to over 45,000 hospitals and clinics
- Our TB and MDR-TB messages have reached millions of people in high-risk populations through innovative public awareness campaigns
- Over 350 journalists have been educated and trained to report on the disease in ways appropriate to their culture
- Our work has been recognized at the highest level, and we have received international awards from the Clinton Initiative, International Chamber of Commerce and Global Business Coalition on Health